Stocktoria
Kyverna Therapeutics, Inc. KYTX
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2024-02-08
Kyverna Therapeutics, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| R&D expense | $133.7M | $112.5M | $49.9M |
| Operating income | -$169.8M | -$142.6M | -$62.4M |
| Income tax | $0 | $0 | $0 |
| Net income | -$161.3M | -$127.5M | -$60.4M |
| EPS (diluted) | $-3.64 | $-3.33 | $-89.61 |
| Operating cash flow | -$153.7M | -$114.2M | -$52.4M |
| Free cash flow | -$153.7M | -$116.5M | -$53.0M |
| Cash & equivalents | $124.1M | $96.6M | $34.6M |
| Total assets | $293.8M | $304.6M | $75.2M |
| Total liabilities | $61.5M | $38.1M | $26.0M |
| Shareholders' equity | $232.3M | $266.6M | -$13.1M |
Source: SEC EDGAR filings · CIK 0001994702 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.